Molecular therapies and precision medicine for hepatocellular carcinoma

JM Llovet, R Montal, D Sia, RS Finn - Nature reviews Clinical oncology, 2018‏ - nature.com
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

[PDF][PDF] Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference

JM Llovet, A Villanueva, JA Marrero, M Schwartz… - …, 2021‏ - Wiley Online Library
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

[HTML][HTML] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet… - Annals of oncology, 2018‏ - Elsevier
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a …

MK He, QJ Li, RH Zou, JX Shen, WQ Fang… - JAMA …, 2019‏ - jamanetwork.com
Importance Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein
invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic …

EASL clinical practice guidelines: management of hepatocellular carcinoma

PR Galle, A Forner, JM Llovet, V Mazzaferro… - Journal of …, 2018‏ - Elsevier
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Current and future treatment of hepatocellular carcinoma: an updated comprehensive review

S Daher, M Massarwa, AA Benson… - Journal of clinical and …, 2017‏ - pmc.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality.
The principal treatment is surgical resection or liver transplantation, depending on whether …

[HTML][HTML] EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma

European Association For The Study Of … - Journal of …, 2012‏ - journal-of-hepatology.eu
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Treatment of liver cancer

CY Liu, KF Chen, PJ Chen - Cold Spring …, 2015‏ - perspectivesinmedicine.cshlp.org
Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …

[HTML][HTML] EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma

EO for Research… - Journal of …, 2012‏ - Elsevier
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

[HTML][HTML] Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a …

LT Chen, E Martinelli, AL Cheng, G Pentheroudakis… - Annals of …, 2020‏ - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma …